Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blin...
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
About this item
Full title
Author / Creator
Publisher
United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Journal title
Language
English
Formats
Publication information
Publisher
United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subjects
More information
Scope and Contents
Contents
Linaclotide is a guanylate cyclase-C agonist approved in the United States, Canada, and Mexico at a once-daily 145-μg dose for the treatment of chronic idiopathic constipation (CIC); a once-daily 72-μg dose for CIC recently received FDA approval. The trial objective was to evaluate the efficacy and safety of a 72-μg linaclotide dose in CIC patients...
Alternative Titles
Full title
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1985905945
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1985905945
Other Identifiers
ISSN
0002-9270
E-ISSN
1572-0241
DOI
10.1038/ajg.2017.230
